Hologic (NASDAQ:HOLX) Issues FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 4.250-4.350 for the period, compared to the consensus estimate of 4.070. The company issued revenue guidance of $4.2 billion-$4.2 billion, compared to the consensus revenue estimate of $4.0 billion. Hologic also updated its FY25 guidance to $4.25-4.35 EPS.

Analyst Ratings Changes

A number of analysts have commented on the company. Leerink Partners decreased their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. JPMorgan Chase & Co. increased their target price on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday. Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Mizuho increased their target price on Hologic from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. Finally, Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average target price of $88.00.

Hologic Stock Down 4.8 %

NASDAQ HOLX traded down $4.01 during midday trading on Tuesday, hitting $79.71. 1,370,348 shares of the company traded hands, compared to its average volume of 1,581,496. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The company has a market cap of $18.51 billion, a PE ratio of 27.10, a price-to-earnings-growth ratio of 2.98 and a beta of 0.98. The company’s 50-day simple moving average is $81.06 and its 200-day simple moving average is $78.08. Hologic has a 52 week low of $66.93 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business posted $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities research analysts forecast that Hologic will post 4.09 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.